HS 20094
Alternative Names: HS-20094Latest Information Update: 30 Aug 2024
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 21 Jan 2024 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
- 16 Oct 2023 Phase-II clinical trials in Obesity (In volunteers) in China (SC) (NCT06118021)
- 30 May 2023 Phase-II clinical trials in Type 2 diabetes mellitus (In adults) in China (SC) (NCT06118008)